Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 6/20 | 0.55 |
| ▸ | JAK2 | O60674 | 1/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | JUN | P05412 | 4/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | FGFR4 | P22455 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | AXL | P30530 | 1/20 | 0.47 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.47 |
| ▸ | MERTK | Q12866 | 1/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1632167 | 0.88 | MAPK10 (0.57) | MAPK10JAK2BRD4JUNMAPK8 | |
| SCHEMBL1633192 | 0.86 | JAK2 (0.55) | MAPK10JAK2BRD4JUNMAPK8 | |
| SCHEMBL1633868 | 0.85 | MAPK10 (0.57) | MAPK10JAK2JUNMAPK8CDK2 | |
| SCHEMBL1633468 | 0.84 | MAPK10 (0.51) | MAPK10JAK2BRD4JUNMAPK8 | |
| SCHEMBL1633048 | 0.82 | MAPK10 (0.66) | MAPK10JAK2BRD4JUNMAPK8 | |
| SCHEMBL18377031 | 0.82 | JAK2 (0.55) | MAPK10JAK2BRD4JUNMAPK8 | |
| SCHEMBL1633250 | 0.81 | AXL (0.52) | MAPK10JAK2BRD4JUNMAPK8 | |
| SCHEMBL1634206 | 0.80 | CTSC (0.52) | MAPK10JAK2BRD4JUNMAPK8 | |
| SCHEMBL1631590 | 0.79 | MAPK10 (0.50) | MAPK10JUNMAPK8AXLTYRO3 | |
| SCHEMBL18376655 | 0.78 | JAK2 (0.67) | JAK2BRD4FGFR4CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | MAPK10 402/4885JAK2 1352/4885BRD4 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.